Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following salvage radiotherapy (sRT) informed by prostate-specific membrane antigen ...

For the hundreds of thousands of men who undergo radical prostatectomy each year, one question looms over every postoperative ...

PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer.

A UCLA-led study has found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to ...

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment ...

Credit: Getty Images Study reveals factors that could distinguish PSA bounce from biochemical recurrence after stereotactic body radiation therapy for prostate cancer. Investigators have identified ...

− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered – MONROE TOWNSHIP, N.J. & ...

Treatments intended to reduce biochemical recurrence in patients with prostate cancer may not improve long-term survival, recent research showed. Certain prostate cancer treatments used to reduce the ...